Teva’s At-Risk Launch Of Pulmicort Generics May Cost It Exclusivity
Executive Summary
Teva's exclusivity clock may already be ticking following the short-lived launch of a generic version of AstraZeneca's Pulmicort. Generic sales for the product are now suspended by court order with a hearing on the preliminary injunction scheduled for Nov. 25
You may also be interested in...
Actavis’ Launch Of Pulmicort Respules Generic Halted By Court
One day after declaring one Pulmicort patent invalid and another not infringed, a New Jersey federal judge granted AstraZeneca’s bid to temporarily block Actavis and other ANDA filers from launching and distributing their budesonide generics.
Teva Settlements Stick To Date of Entry Even As Legislative Debate Continues
Teva is taking a cautious approach in its patent settlements with brand firms - inking deals that meet the strict standards of pending legislation even as the bills are still under debate
Teva Settlements Stick To Date of Entry Even As Legislative Debate Continues
Teva is taking a cautious approach in its patent settlements with brand firms - inking deals that meet the strict standards of pending legislation even as the bills are still under debate